MSB 7.76% $1.88 mesoblast limited

Does one know something that the other doesn't?

  1. 875 Posts.
    lightbulb Created with Sketch. 299
    FINANCIAL REVIEW

    Mesoblast remains an "underperform" recommendation at Macquarie Wealth Management. "In the absence of finding partners to co-develop its products, we envisage significant funding difficultly for MSB in coming years. And given the ongoing trend of big pharma moving away from adult-derived stem-cell therapeutics, we believe finding partners will not be an easy exercise." Price target is $1.33 a share, says Macquarie. In the US, where MESO shares are down about 50 per cent post US relisting, JPMorgan has initiated coverage of Mesoblast (MESO) with an "overweight" rating and December 2016 price target of $US10 (currently trading around $US6).
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.88
Change
0.135(7.76%)
Mkt cap ! $1.128B
Open High Low Value Volume
$1.77 $1.91 $1.77 $6.386M 3.441M

Buyers (Bids)

No. Vol. Price($)
5 4446 $1.87
 

Sellers (Offers)

Price($) Vol. No.
$1.88 4495 3
View Market Depth
Last trade - 13.34pm 17/05/2021 (20 minute delay) ?
(live)
Last
$1.86
  Change
0.135 ( 6.66 %)
Open High Low Volume
$1.78 $1.90 $1.78 628630
Last updated 13.52pm 17/05/2021 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.